A Study of the Pharmacokinetic and Safety Profile of QID Dosing of Mibefradil in Normal Human Volunteers.

Trial Profile

A Study of the Pharmacokinetic and Safety Profile of QID Dosing of Mibefradil in Normal Human Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Mibefradil (Primary)
  • Indications Glioblastoma; Glioma; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Cavion
  • Most Recent Events

    • 11 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Additional trial identifier NCT01550458 and investigators identified, inclusion-exclusion criteria amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top